Sugi Predict

Sugi Predict / Compounds / SCHEMBL203205

SCHEMBL203205

SCHEMBL203205

O=C(O)c1ccc2cc(Br)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 1/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ SRD5A1 P18405 1/20 0.55
▸ SRD5A2 P31213 1/20 0.55
▸ CYP2A6 P11509 1/20 0.48
▸ PIM1 P11309 1/20 0.47
▸ PTPN1 P18031 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ENPP2 Q13822 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MMP2 P08253 1/20 0.45
▸ MMP9 P14780 1/20 0.45
▸ MMP8 P22894 1/20 0.45
▸ MMP13 P45452 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30020656 1.00 DHODH (0.55) DHODHKDM4ESRD5A1SRD5A2CYP2A6
Hydrochloric Acid SCHEMBL1001004 0.98 DHODH (0.54) DHODHKDM4ESRD5A1SRD5A2CYP2A6
SCHEMBL2049058 0.94 SRD5A1 (0.53) DHODHKDM4ESRD5A1SRD5A2CYP2A6
Methoxymethane SCHEMBL27807143 0.92 KDM4E (0.62) DHODHKDM4ESRD5A1SRD5A2MEN1
SCHEMBL1769873 0.91 LCK (0.55) DHODHKDM4ESRD5A1SRD5A2CYP2A6
SCHEMBL10081752 0.90 PTPN1 (0.53) DHODHKDM4ESRD5A1SRD5A2PIM1
SCHEMBL29359975 0.86 KDM4E (0.68) KDM4ESRD5A2PTPN1TP53TSHR
SCHEMBL29594563 0.86 KDM4E (0.68) KDM4ESRD5A2PTPN1TP53TSHR
SCHEMBL18758 0.86 KDM4E (0.68) KDM4ESRD5A2PTPN1TP53TSHR
SCHEMBL6916181 0.86 KDM4E (0.68) KDM4ESRD5A2PTPN1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118666667-A Preparation method of adapalene EP impurity A 湖北广济医药科技有限公司 2024-09-20 — — CN claimed
CN-117700298-A Preparation method of hydroxyl adapalene 湖北广济药业股份有限公司 2024-03-15 — — CN claimed
CN-116943622-A Preparation method of molecularly imprinted activated carbon for targeted degradation of naphthalene 同济大学 2023-10-27 — — CN claimed
CN-111636208-B Mesoporous hydrogen bond organic framework fiber composite material and preparation method and application thereof 李鹏 2022-10-11 — — CN claimed
CN-216986707-U 6-bromo-2-naphthoic acid waste water recovery filter equipment 上海辅欣医药科技有限公司 2022-07-19 — — CN claimed
CN-109438230-B Synthetic method of adapalene intermediate 6-bromo-2-naphthoate 深圳市第二人民医院 2022-04-22 — — CN claimed
CN-213333180-U A mounting bracket for 6-bromo-2-naphthoic acid production facility 山东星顺新材料有限公司 2021-06-01 — — CN claimed
CN-213326977-U Wastewater collection and treatment device for 6-bromo-2-naphthoic acid production 山东星顺新材料有限公司 2021-06-01 — — CN claimed
CN-212975075-U Positioning device of 6-bromo-2-naphthoic acid production equipment 山东星顺新材料有限公司 2021-04-16 — — CN claimed
CN-212974944-U Agitating unit is used in production of 6-bromo-2-naphthoic acid raw materials 山东星顺新材料有限公司 2021-04-16 — — CN claimed
EP-1868980-A2 NEW METHOD FOR THE PREPARATION OF 6-(3-(1-ADAMANTYL)-4-METHOXPHENYL)-2-NAPHTHOIC ACID Galderma Research & Development (FR) 2007-12-26 — — EP claimed
US-7273856-B2 Linear basic compounds having NK-2 antagonist activity and formulations thereof MENARINI RICERCHE S.P.A. (IT) 2007-09-25 — — US claimed
WO-2006108717-A2 NEW METHOD FOR THE PREPARATION OF 6-(3-(1-ADAMANTYL)-4-METHOXPHENYL)-2-NAPHTHOIC ACID GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-19 — — WO claimed
EP-1442050-B1 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI SAS (IT) 2006-09-13 — — EP claimed
CN-1696100-A Now short cutting method for synthcsizing Adpalin dryg trcatubg acnc WU GUANGYAN (CN) 2005-11-16 — — CN claimed
CN-1578786-A Linear basic compounds having NK-2 antagonistic activity and formulations thereof MENARINI RICERCHE SPA (IT) 2005-02-09 — — CN claimed
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) 2004-12-23 — — US claimed
EP-1442050-A2 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) 2004-08-04 — — EP claimed
WO-2003037916-A2 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) 2003-05-08 — — WO claimed
US-4748227-A Process for preparing poly(aryl ether)ketones using a sodium carbonate/organic acid salt catalyst AMOCO CORPORATION (US) 1988-05-31 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof BDKRB2, BDKRB1, TACR2 DHODH 3356/4885KDM4E 3285/4885SRD5A1 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.